Lineage Cell Therapeutics, Inc. (LCTX): who owns it and who trades it
As of Nov 16, 2026, LCTX insiders reported 2 purchases worth $41.5K in the last 12 months. The largest buyer was Brian M Culley (CEO), with $24.4K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Lineage Cell Therapeutics
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LCTX
131 funds and institutions reported LCTX shares worth $153M at the end of Q2 2026, about 47% of the company. The largest holder is Broadwood Capital Inc with 19.9%.
Funds and institutions (13F) 47%Everyone else 53%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Broadwood Capital Inc | 49.56M | 19.90% | $64.9M | No change |
| BlackRock, Inc. | 13.19M | 5.29% | $17.3M | +241% |
| Vanguard Capital Management LLC | 9.05M | 3.64% | $11.9M | +9% |
| Defender Capital, LLC. | 6.60M | 2.65% | $8.6M | -2% |
| Geode Capital Management, LLC | 5.30M | 2.13% | $6.9M | +110% |
| Raffles Associates LP | 5.20M | 2.09% | $6.8M | -3% |
| Fifth Third Bancorp | 4.60M | 1.85% | $6M | No change |
| Millennium Management LLC | 3.02M | 1.21% | $4M | -46% |
| State Street Corp | 2.31M | 0.93% | $3M | +112% |
| Vanguard Fiduciary Trust Co | 1.67M | 0.67% | $2.2M | +26% |
| Northern Trust Corp | 1.66M | 0.67% | $2.2M | +232% |
| Morgan Stanley | 1.47M | 0.59% | $1.9M | -21% |
| Renaissance Technologies LLC | 1.34M | 0.54% | $1.8M | -37% |
| Marshall Wace, LLP | 1.28M | 0.51% | $1.7M | -58% |
| Vanguard Portfolio Management LLC | 1.27M | 0.51% | $1.7M | – |
| UBS Group AG | 687,051 | 0.28% | $900K | -50% |
| Red Crane Wealth Management, LLC | 597,263 | 0.24% | $782K | No change |
| Charles Schwab Investment Management Inc | 577,435 | 0.23% | $756K | +344% |
| Sixth Street Partners Management Company, L.P. | 577,435 | 0.23% | $756K | – |
| Barclays PLC | 508,668 | 0.20% | $666K | +29% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LCTX insiders reported $41.5K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Jill Ann Howe | CFO | Purchase | 20,000 | $0.85 | $17.1K | Form 4 |
| Mar 12, 2026 | Brian M Culley | CEO | Purchase | 15,000 | $1.63 | $24.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Brian M Culley | President and CEO, Director | $24.4K | – | Mar 12, 2026 |
| Jill Ann Howe | Chief Financial Officer | $17.1K | – | Nov 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LCTX short interest
Moderate short interest. 9.6% of LCTX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 6%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 24.35M LCTX shares were sold short, 9.6% of the shares outstanding, down 6.1% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 19.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 24.35M | 9.63% | -6% | 1.26M | 19.3 |
| Oct 15, 2026 | 25.93M | 10.25% | -11% | 1.55M | 16.8 |
| Sep 30, 2026 | 29.09M | 11.50% | -1% | 1.85M | 15.8 |
| Sep 15, 2026 | 29.47M | 11.65% | +2% | 1.11M | 26.6 |
| Aug 31, 2026 | 28.98M | 11.46% | +2% | 876,205 | 33.1 |
| Aug 14, 2026 | 28.33M | 11.20% | -4% | 808,109 | 35.1 |
| Jul 31, 2026 | 29.56M | 11.87% | -1% | 1.13M | 26.2 |
| Jul 15, 2026 | 29.87M | 11.99% | +6% | 862,087 | 34.6 |
| Jun 30, 2026 | 28.19M | 11.32% | +10% | 3.38M | 8.3 |
| Jun 15, 2026 | 25.56M | 10.26% | -2% | 1.11M | 23.0 |
| May 29, 2026 | 26.08M | 10.47% | +1% | 1.05M | 25.0 |
| May 15, 2026 | 25.92M | 10.40% | +1% | 1.55M | 16.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Lineage Cell Therapeutics company events
Lineage Cell Therapeutics filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 6, 2026.
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 12, 2026AnnouncementAs previously reported, in January 2026, the Company applied for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine to support continued clinical development of OPC1 for the treatment of spinal cord injuries. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 11, 2026AnnouncementLineage Cell Therapeutics, Inc. filed with the U.S. Securities and Exchange Commission a prospectus supplement dated March 11, 2026 to the prospectus dated May 14, 2024 that forms a part of the Company’s shelf registration statement on Form S-3 (File No. 333-277758) filed by the Company with the… Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Nov 28, 2025AnnouncementAs previously reported, Lineage Cell Therapeutics, Inc. applied for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine in June 2025 to support continued clinical development of OPC1 for the treatment of spinal cord injuries. Filing
- Nov 24, 2025AnnouncementAs previously reported, in December 2021, Lineage Cell Therapeutics, Inc., entered into a collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. under which our lead cell therapy program known as OpRegen® (also known as RG6501) is being developed for the treatment of… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Lineage Cell Therapeutics financials
Famous investors that hold LCTX
4 of the 50 well-known investors we track reported holding LCTX in their latest 13F filing. The largest position is Israel Englander's, worth $2.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 2.63M | $2.5M | 0.0% | -13% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 674,529 | $645K | 0.0% | -50% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 341,881 | $327K | 0.0% | -20% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 29,128 | $27.8K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Lineage Cell Therapeutics, Inc. (LCTX) stock
Who owns the most LCTX stock?
The largest reported owner of Lineage Cell Therapeutics, Inc. (LCTX) is Broadwood Capital Inc, with 19.9% of the company. In total, 131 funds and institutions reported holding LCTX at the end of Q2 2026, together about 47% of the shares. See the largest owners.
Are LCTX insiders buying or selling?
In the last 12 months, LCTX insiders reported 2 open-market purchases worth $41.5K and no sales. The latest trade was on Nov 16, 2026. See every trade.
What is the short interest in LCTX?
As of Oct 30, 2026, 24.35M LCTX shares were sold short, 9.6% of the shares outstanding, down 6.1% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 19.3 trading days (days to cover). See the history.
Which famous investors hold LCTX?
4 of the 50 well-known investors we track reported LCTX in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $2.5M. See all holders.
Executive pay
Lineage Cell Therapeutics's chief executive was paid a total of $2.1M for the year ended Dec 31, 2025, down 17% from $2.5M the year before. In the last 12 months, Lineage Cell Therapeutics's executives and directors bought $41.5K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.